December 21, 2016 / 12:31 PM / 8 months ago

BRIEF-Oasmia Pharma reports positive results from study on weekly administration of Apealea

Dec 21 (Reuters) - Oasmia Pharmaceutical Ab

* Oasmia Pharmaceutical AB says an overall analysis of all adverse events recorded in study defined 180 mg/m as level for dose-limiting toxicity

* Oasmia Pharmaceutical reports positive results from study on weekly administration of Apealea

* Oasmia Pharmaceutical AB says pre-defined, dose-limiting toxicity as defined in study protocol was not reached until 250 mg/m per week Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below